Stigma Grow

Data Snapshot: Nov 04, 2024
Stigma Grow Cannabis Brand Logo
$100K+

Oct-2024

Sales

Decline

Trend

6-Month

11

Product Count

SKUs

Stigma Grow

Overview

Stigma Grow is a pioneering Alberta-based company, specializing in the cultivation of top-tier cannabis and the extraction of high-terpene cannabis extracts. As a wholly owned subsidiary of the Canadian cannabis company, CanadaBis Capital, it strives to offer consumers highly potent and quality-driven cannabis products. Recognised in the "Green Rush" of the cannabis industry, Stigma Grow stands out for its innovative approach to cannabis cultivation and extraction techniques, highlighting a global future perspective on cannabis as a potentially mainstream pain medicine.
Markets

Stigma Grow Locations

Product Trends

Stigma Grow Categories

Stigma Grow Sales

Market Insights Snapshot

Stigma Grow Historical Sales by Category

Stigma Grow has demonstrated a varied performance across different product categories and regions, with notable movements in their rankings. In the Capsules category, the brand remains a strong contender in Alberta, maintaining a top 5 position throughout the months, though slipping from 2nd to 4th place by October 2024. This suggests a slight decline in market share, although the difference in ranking is not drastic. In Ontario, Stigma Grow improved its standing in the Capsules category, climbing from 10th to 9th place, indicating a positive reception and potential growth in this market. Meanwhile, in British Columbia, the brand consistently held the 7th position, showing stability in consumer demand for its Capsules.

In the Concentrates category, Stigma Grow's performance was mixed. In Alberta, the brand showed resilience, moving from 18th to 16th place by October, indicating a recovery in market position despite earlier fluctuations. However, in Ontario, the brand did not feature in the top 30 in July, which can be seen as a challenge for the brand in this category within the province. Though they improved to 54th place by October, it highlights the difficulty in gaining traction in this particular market. Conversely, British Columbia saw a similar pattern of improvement, with the brand rising from 19th to 16th, suggesting a growing acceptance of their concentrates among consumers in this region. Overall, Stigma Grow's trajectory in these categories and regions points to both opportunities and challenges, with certain areas showing promise for growth while others require strategic attention.

Oct-2024 Rank
Capsules
Concentrates
4
16
7
16
9
54
Stigma Grow

Competitive Landscape

In the Alberta capsules market, Stigma Grow has experienced a notable shift in its competitive positioning over the past few months. Initially ranked second in July 2024, Stigma Grow has seen a gradual decline, moving to third place in August and September, and then to fourth place in October. This decline in rank is accompanied by a decrease in sales, contrasting with the consistent top position held by Glacial Gold, which has maintained its lead with increasing sales each month. Meanwhile, Tweed has shown a positive trend, improving its rank from being unlisted in July to securing the third position by October, indicating a competitive threat to Stigma Grow. Additionally, Emprise Canada and Frank have remained relatively stable in their rankings, with Frank showing a slight improvement in October. These dynamics suggest that Stigma Grow needs to reassess its strategies to regain its competitive edge and address the challenges posed by its competitors in the Alberta capsules market.

Stigma Grow market ranking for AB Capsules

Stigma Grow

Notable Products

In October 2024, Stigma Grow's top-performing product was the Indica RSO Capsules 25-Pack (250mg) in the Capsules category, maintaining its number one rank consistently from July through October with sales of 5270 units. The Phoenix Tears RSO (1g) in the Concentrates category held steady at the second position throughout these months, showing a notable increase in sales to 3442 units in October. The CBD Softgels 15-Pack (750mg CBD), also in the Capsules category, consistently ranked third, though sales have been decreasing over the months. Meanwhile, the Phoenix Tears Resin (1g) saw improvement in its ranking, moving from fifth in August to fourth in October. Lastly, Phoenix Tears Honey Oil (1g) maintained its fifth position, with only slight fluctuations in sales figures.

Product Rank
Category
Jul-2024
Aug-2024
Sep-2024
Oct-2024
Indica RSO Capsules 25-Pack (250mg)
Capsules
1
1
1
1
Phoenix Tears RSO (1g)
Concentrates
2
2
2
2
CBD Softgels 15-Pack (750mg CBD)
Capsules
3
3
3
3
Phoenix Tears Resin (1g)
Concentrates
>5
5
4
4
Phoenix Tears Honey Oil (1g)
Concentrates
4
4
5
5
View product & sales data

Top Selling Cannabis Brands

Simple, transparent pricing that grows with you. Try any plan free for 30 days.
Research the top cannabis brands across markets in the US and Canada.

Data for this report comes from real-time sales reporting by participating cannabis retailers via their point-of-sale systems, which are linked up with Headset’s business intelligence software. Headset’s data is very reliable, as it comes digitally direct from our partner retailers. However, the potential does exist for misreporting in the instance of duplicates, incorrectly classified products, inaccurate entry of products into point-of-sale systems, or even simple human error at the point of purchase. Thus, there is a slight margin of error to consider. Brands listed on this page are ranked in the top twenty within the market and product category by total retail sales volume.

Header image
User rating
start Today
Connect to Headset

Get Cannabis Market Data